Zeldes Haeggquist & Eck, LLP, a shareholder and consumer rights litigation firm has commenced an investigation into Prana Biotechnology Limited (“Prana Biotechnology” or the “Company”) (NASDAQ: PRAN). The investigation is related to potential violations of federal securities laws and other violations.
Prana Biotechnology researches and develops therapeutic drugs for the treatment of neurological disorders. The Company’s product line includes PBT2, which is in Phase II clinical trials for the treatment of Alzheimer’s disease.
On March 31, 2014, Prana Biotechnology reported disappointing results from PBT2’s phase II Alzheimer’s Disease trial. PBT2 failed to significantly reduce levels of betamyloid plaques in the brains of mild Alzheimer’s disease patients. Patients in the PBT2 study showed a reduction in the plaque presence, but so did the placebo group. There was also a lack of improvement in brain metabolic activity, cognition, and function. Upon these revelations, the price of Prana Biotechnology shares dropped significantly.
What You Can Do
If you are a Prana Biotechnology shareholder, you may have legal claims against Prana Biotechnology Officers and Directors. If you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Amber L. Eck at (619) 342-8000 or via email at firstname.lastname@example.org.